Acute and chronic kidney disease encompasses a complex set of diseases that can both
lead to, and result from, cancer. In particular, kidney disease can arise from the use of …

Abstract Background and Aims Atezolizumab plus bevacizumab (AtezoBev) is the standard
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …

Cancer is the second leading cause of death in people with chronic kidney disease (CKD)
after cardiovascular disease. The incidence of CKD in patients with cancer is higher than in …

Photodynamic therapy (PDT) works through photoactivation of a specific photosensitizer
(PS) in a tumor in the presence of oxygen. PDT is widely applied in oncology to treat various …

Cytochrome P450 3A4 (CYP3A4), one of the most important members of the cytochrome
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …

Conventional chemotherapies remain the mainstay of treatment for many malignancies.
Kidney complications of these therapies are not infrequent and may have serious …

Albumin, as the most abundant plasma protein, plays an integral role in the transport of a
variety of exogenous and endogenous ligands in the bloodstream and extravascular …

We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated
with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen …

The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review …

Anaplastic lymphoma kinase (ALK) inhibitors are important treatment options for non-small-
cell lung cancer (NSCLC), associated with ALK gene rearrangement. Patients with ALK …